Sinopharm Group Co. Ltd. (SHTDY)
USD 11.62
(0.96%)
USD 11.62
(0.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 48.51 Billion CNY | 2.27% |
| 2022 | 47.43 Billion CNY | 7.68% |
| 2021 | 44.05 Billion CNY | 9.24% |
| 2020 | 40.32 Billion CNY | 7.44% |
| 2019 | 37.53 Billion CNY | 20.18% |
| 2018 | 31.22 Billion CNY | 39.48% |
| 2017 | 22.38 Billion CNY | 9.75% |
| 2016 | 20.4 Billion CNY | 9.81% |
| 2015 | 18.57 Billion CNY | 13.77% |
| 2014 | 16.32 Billion CNY | 22.05% |
| 2013 | 13.37 Billion CNY | 22.26% |
| 2012 | 10.94 Billion CNY | 30.98% |
| 2011 | 8.35 Billion CNY | 43.16% |
| 2010 | 5.83 Billion CNY | 54.2% |
| 2009 | 3.78 Billion CNY | 24.7% |
| 2008 | 3.03 Billion CNY | 19.01% |
| 2007 | 2.55 Billion CNY | 28.18% |
| 2006 | 1.98 Billion CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 10.57 Billion CNY | -20.57% |
| 2024 Q2 | 11.36 Billion CNY | 7.49% |
| 2023 Q3 | 11.92 Billion CNY | -3.27% |
| 2023 FY | 48.51 Billion CNY | 2.27% |
| 2023 Q1 | 10.94 Billion CNY | -18.28% |
| 2023 Q4 | 13.31 Billion CNY | 11.64% |
| 2023 Q2 | 12.32 Billion CNY | 12.69% |
| 2022 Q4 | 13.38 Billion CNY | 8.06% |
| 2022 Q1 | 10.01 Billion CNY | -13.55% |
| 2022 FY | 47.43 Billion CNY | 7.68% |
| 2022 Q2 | 11.64 Billion CNY | 16.35% |
| 2022 Q3 | 12.38 Billion CNY | 6.37% |
| 2021 FY | 44.05 Billion CNY | 9.24% |
| 2021 Q3 | 11.88 Billion CNY | 4.54% |
| 2021 Q2 | 11.36 Billion CNY | 23.32% |
| 2021 Q4 | 11.57 Billion CNY | -2.57% |
| 2021 Q1 | 9.21 Billion CNY | -20.28% |
| 2020 Q2 | 9.94 Billion CNY | 36.31% |
| 2020 Q4 | 11.56 Billion CNY | 0.4% |
| 2020 Q3 | 11.51 Billion CNY | 15.81% |
| 2020 Q1 | 7.29 Billion CNY | -29.21% |
| 2020 FY | 40.32 Billion CNY | 7.44% |
| 2019 Q3 | 9.73 Billion CNY | -0.62% |
| 2019 FY | 37.53 Billion CNY | 20.18% |
| 2019 Q1 | 7.68 Billion CNY | -11.16% |
| 2019 Q2 | 9.8 Billion CNY | 27.54% |
| 2019 Q4 | 10.3 Billion CNY | 5.83% |
| 2018 Q2 | 8.01 Billion CNY | 24.32% |
| 2018 FY | 31.22 Billion CNY | 39.48% |
| 2018 Q1 | 6.44 Billion CNY | -14.93% |
| 2018 Q3 | 8.11 Billion CNY | 1.25% |
| 2018 Q4 | 8.64 Billion CNY | 6.58% |
| 2017 FY | 22.38 Billion CNY | 9.75% |
| 2017 Q3 | 7.57 Billion CNY | 39.15% |
| 2017 Q4 | 7.57 Billion CNY | 0.0% |
| 2017 Q1 | 5.44 Billion CNY | 4.76% |
| 2017 Q2 | 5.44 Billion CNY | 0.0% |
| 2016 Q1 | 5.04 Billion CNY | 5.36% |
| 2016 Q4 | 5.19 Billion CNY | 0.0% |
| 2016 Q3 | 5.19 Billion CNY | -0.53% |
| 2016 Q2 | 5.22 Billion CNY | 3.54% |
| 2016 FY | 20.4 Billion CNY | 9.81% |
| 2015 Q2 | 4.63 Billion CNY | 2.78% |
| 2015 Q3 | 4.79 Billion CNY | 3.42% |
| 2015 Q4 | 4.79 Billion CNY | 0.0% |
| 2015 FY | 18.57 Billion CNY | 13.77% |
| 2015 Q1 | 4.5 Billion CNY | 6.41% |
| 2014 FY | 16.32 Billion CNY | 22.05% |
| 2014 Q4 | 4.23 Billion CNY | 0.0% |
| 2014 Q3 | 4.23 Billion CNY | 7.82% |
| 2014 Q2 | 3.92 Billion CNY | 0.0% |
| 2014 Q1 | 3.92 Billion CNY | 11.37% |
| 2013 Q1 | 3.16 Billion CNY | 0.0% |
| 2013 FY | 13.37 Billion CNY | 22.26% |
| 2013 Q2 | 3.16 Billion CNY | 0.0% |
| 2013 Q4 | 3.52 Billion CNY | 0.0% |
| 2013 Q3 | 3.52 Billion CNY | 11.55% |
| 2012 FY | 10.94 Billion CNY | 30.98% |
| 2011 FY | 8.35 Billion CNY | 43.16% |
| 2010 FY | 5.83 Billion CNY | 54.2% |
| 2009 FY | 3.78 Billion CNY | 24.7% |
| 2008 FY | 3.03 Billion CNY | 19.01% |
| 2007 FY | 2.55 Billion CNY | 28.18% |
| 2006 FY | 1.98 Billion CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| China Medicine Corporation | 18.98 Million USD | -255434.563% |
| DH Enchantment Inc. | -406.00 USD | 11948689262.562% |
| Exlites Holdings International, Inc. | 18.74 Thousand USD | -258866911.74% |
| Itonis, Inc. | 1801.00 USD | -2693596679.567% |
| One Step Vending Corp. | -1238.00 USD | 3918552442.488% |
| MediPal Holdings Corporation | 1.53 Billion USD | -3051.165% |
| PD-Rx Pharmaceuticals, Inc. | 6.71 Million USD | -722549.289% |
| Pharmagen, Inc. | 3045.21 USD | -1593048589.581% |
| Suzuken Co., Ltd. | 1.22 Billion USD | -3863.566% |